Medtech Big 100: Just missed the list
No. 102: Axonics
Revenue: $273,702,000
R&D expenditures: $34,410,000
Employees: 610
CEO: Raymond Cohen
HQ: Irvine, California
www.axonics.com
Axonics makes a sacral neuromodulation (SNM) system that is designed to treat overactive bladder and fecal incontinence. Axonics Therapy offers a choice between two long-lasting implant device options: Axonics F15 and Axonics R20. The F15 system is a recharge-free SNM therapy option, providing therapy for 10 to 20 years. Its small and thin design is made for patient comfort and allows patients to safely undergo a full-body MRI. The R20 system is a miniaturized, rechargeable device that provides therapy for 20 or more years. It can be used for six to 10 months between charges and allows patients to safely undergo a full-body MRI.
![An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2025/04/Edwards-Lifesciences-Sapien-M3-TMVR-valve-delivery-268x170.jpg)